Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry
Allergy
.
2024 May 7.
doi: 10.1111/all.16147.
Online ahead of print.
Authors
D Stölzl
1
,
N Sander
1
,
D Siegels
2
,
I Harder
1
,
B Kind
2
,
M Fonfara
1
,
L Heinrich
2
,
S Abraham
3
,
I Neustädter
4
,
A Kleinheinz
5
,
S Gerdes
1
,
A Wollenberg
6
7
,
S Lau
8
,
K Nemat
9
,
A Heratizadeh
10
,
I Gellhaus
11
,
T Werfel
10
,
J Schmitt
2
,
S Weidinger
1
;
TREATgermany study group
Affiliations
1
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
2
Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
3
Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
4
Cnopfsche Children's Hospital/Neonatology, Pediatrics, DIAKONEO KdöR, Nuremberg, Germany.
5
Clinics for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.
6
Clinics and Outpatient Clinics for Dermatology and Allergy, LMU Munich, Munich, Germany.
7
Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany.
8
Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
9
Praxis für Kinderpneumologie/Allergologie, Kinderzentrum Dresden-Friedrichstadt, Dresden, Germany.
10
Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
11
Rehaforschung Nord e.V, Sylt, Germany.
PMID:
38712730
DOI:
10.1111/all.16147
No abstract available
Publication types
Letter
Grants and funding
Funding sources: TREATgermany is an academic, investigator-initiated clinical disease registry that is financially supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc. and Sanofi.